. Mean anion gap in myeloma patients and controls
Discussion
The anion gap in the myeloma patients studied here was significantly less than that of the control groups. This has been found in earlier studies with fewer patientsv". The differing results between IgG and IgA paraproteins has been explained on the basis of IgG being a cationic paraprotein whilst IgA is anionic", However, some of our IgA patients did have low anion gaps, unlike the studies cited above where all the IgA patients had normal anion gaps. examined in this latter group. Patients classified as cases of 'benign paraproteinaemia', or 'monoclonal gammopathy of undetermined significance' (MGUS), are followed up regularly here, and results from 71 of these aged 65 years or over were available for inspection. One hundred aged-matched subjects in local rest homes, none of whom was having medical treatment at the time of sampling, were used as a second control group. All samples had been examined as part of a routine biochemical profile (Technicon
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Results
The mean anion gap in the three groups is shown in Table 1 . Two patients who were light chain only disease, and had marked renal impairment and very low bicarbonate levels, are not included in Table 1 .
There was a significant difference both between the total myeloma cases and MGUS (P<O.OI) and between the myeloma cases and controls (P<O.OI). The 78 cases were divided into 48 IgG and 30 IgA myelomas. The mean anion gap of the IgG cases was 6.3 and the IgA cases 7.9, giving a P value of < 0.05. Twenty-six of the IgG group (63%) and 11 of the IgA group (34%) had levels below the overall mean. 
Summary
Myeloma in the elderly can mimic many disorders, causing delay in diagnosis. In a retrospective study, the mean anion gap at presentation in 78 elderly patients with confirmed myeloma was found to be significantly less than that of aged-matched controls.
It is suggested that estimation of the anion gap may be useful as a screening test, particularly as it has no intrinsic cost.
Introduction
There are now several well established techniques for staging and monitoring progress in myeloma, e.g. serum beta-2 microglobulin levels and light chain excretion rate. However, these procedures are quite complex and expensive to perform and are in no way suitable for detecting undiagnosed myeloma. Morbidity in myeloma may be significantly less if the disorder can be diagnosed before destructive bone lesions have appeared. Apart from intense pain, lytic bone deposits in the elderly are very likely to lead to prolonged bed rest, with associated problems of respiratory and urinary infection, hypercalcaemia and renal failure. In this area of high incidence of myeloma'P, where more than 70000 people are aged 65 years or over, we have been continually looking for ways to improve our early detection rate. In this respect we have looked again at the anion gap, an estimation which has attracted only passing interest in the UK. It is described here by the equation Na+-(Cl-+HC0 3 ). It has been suggested that a small anion gap noticed in some patients with myeloma is caused by the presence of positively charged, i.e, cationic, myeloma proteins" causing the retention of chloride and bicarbonate. We considered that if this measurement could be shown to be significantly abnormal in our confirmed cases of myeloma at presentation, it would seem reasonable to use it as a screening test to detect occult myeloma. The great advantage would be that the estimation is merely a numerical manipulation and has no intrinsic cost.
In this retrospective study we have examined the anion gap at diagnosis in 78 consecutive cases of myeloma in elderly patients and compared the results with 71 aged-matched patients with benign paraproteinaemia and 100 apparently fit residents of local rest homes.
Patients and methods
One hundred and twenty-nine patients with myeloma have been diagnosed in this department over a period of68 months. Of these, 80 (38 males, 42 females) were 65 years or over. The anion gap at presentation was It has been suggested" that the probability of finding myeloma in a random hospital population is low and it may not be justified to estimate electrolytes for this purpose. We would point out that the incidence of myeloma in the elderly is much greater than in a random population and the patients studied would already have had biochemical investigations for other reasons. Myeloma in the elderly can present in many disguises and diagnosis may be delayed until the typical complications have appeared. Elderly patients often have great difficulty in describing pain and the classical bone pain of myeloma may well be attributed to rheumatic, cardiac, orthopaedic or other causes.
In our experience, other simple screening tests for myeloma have been less helpful than the anion gap. An elevated erythrocyte sedimentation rate (ESR) is a common finding in elderly patients without myeloma, particularly amongst the large population with connective tissue disorders. Conversely, 20% of those patients detailed here had only moderately elevated ESRs. Although a search for background staining of the blood film may be useful sometimes, many large laboratories are unable to scan every film with normal blood parameters. We find background staining and rouleaux most often in those patients with advanced disease where the diagnosis is obvious from other features.
It is important that each laboratory establishes its own normal mean anion gap before searching for abnormality. A system of 'flagging' an abnormal result on a computer printout is very convenient; a quick visual check during a ward round is equally helpful.
In view of the findings in this study, we believe that the anion gap may be a useful additional diagnostic aid indicating the need for more specificinvestigation. All ofthe many tests used in the diagnosis of myeloma may sometimes give misleading results and the anion gap is no exception -a normal level does not exclude myeloma.
More specifictests related to assessment of myeloma cell mass and, therefore, response are preferred to the anion gap in the follow up of patients on treatment.
